Literature DB >> 27238058

Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.

Hacer Durmuş-Tekçe1, Zeliha Matur2, Murat Mert Atmaca1, Mehves Poda3, Arman Çakar1, Ümit Hıdır Ulaş4, Piraye Oflazer-Serdaroğlu1, Feza Deymeer1, Yesim G Parman5.   

Abstract

Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is an autosomal dominant disorder caused by mutations of the transthyretin (TTR) gene. The mutant amyloidogenic transthyretin protein causes the systemic accumulation of amyloid fibrils that result in organ dysfunction. TTR-associated FAP is a progressive and fatal disease, if left untreated, and should be considered in the differential diagnosis of any person presenting with a progressive polyneuropathy, particularly with accompanying autonomic involvement. The clinical, electrophysiological, histopathological, and genetic characteristics of 17 patients from Turkey (5 female, 13 male) from nine families with polyneuropathy and mutations in TTR were evaluated. Sequence analysis of the TTR gene revealed five mutations (Val30Met, Glu89Gln, Gly53Glu, Glu54Gly and Gly47Glu). Mean age at disease onset was 40.4 ± 13.9 years (range 21-66 years). The most commonly reported initial complaint was paresthesia in the feet (asymmetric in three patients). Three patients (2 male) with the Glu89Gln mutation presented with carpal tunnel syndrome. Two patients with the Gly53Glu mutation showed episodes of dysarthria and hemiparesis, consistent with this genotype. Seven patients died during the period of follow-up as a result of systemic involvement. Our study suggests that a cohort of patients from Turkey with TTR-FAP exhibits clinical and genetic heterogeneity.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hereditary; Heterogeneity; Neuropathy; Progressive; Transthyretin-related familial amyloid polyneuropathy

Mesh:

Substances:

Year:  2016        PMID: 27238058     DOI: 10.1016/j.nmd.2016.04.013

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

1.  Lumbar Spinal Stenosis: A Rare Presentation of Hereditary Transthyretin Amyloidosis.

Authors:  Arman Çakar; Murat Mert Atmaca; Dilcan Kotan; Hacer Durmuş; Feza Deymeer; Piraye Oflazer; Yeşim Parman
Journal:  Noro Psikiyatr Ars       Date:  2020-10-11       Impact factor: 1.339

2.  Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area.

Authors:  Massimo Russo; Luca Gentile; Vincenzo Di Stefano; Gianluca Di Bella; Fabio Minutoli; Antonio Toscano; Filippo Brighina; Giuseppe Vita; Anna Mazzeo
Journal:  Brain Sci       Date:  2021-04-27

3.  Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria.

Authors:  Teodora Chamova; Mariana Gospodinova; Ognian Asenov; Tihomir Todorov; Zornitsa Pavlova; Andrey Kirov; Sylvia Cherninkova; Kristina Kastreva; Ani Taneva; Stanislava Blagoeva; Sashka Zhelyazkova; Plamen Antimov; Kaloian Chobanov; Albena Todorova; Ivailo Tournev
Journal:  Front Neurol       Date:  2022-04-08       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.